Cargando…

Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV–Coinfected Patients in Clinical Care

BACKGROUND: There are limited data on the real-world effectiveness of direct-acting antiviral (DAA) treatment in patients coinfected with hepatitis C virus (HCV) and HIV—a population with complex challenges including ongoing substance use, cirrhosis, and other comorbidities. We assessed how patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rossi, Carmine, Young, Jim, Martel-Laferrière, Valérie, Walmsley, Sharon, Cooper, Curtis, Wong, Alexander, Gill, M John, Klein, Marina B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411211/ https://www.ncbi.nlm.nih.gov/pubmed/30882016 http://dx.doi.org/10.1093/ofid/ofz055

Ejemplares similares

Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV
por: Young, Jim, et al.
Publicado: (2017)

Tobacco Smoking Is Not Associated With Accelerated Liver Disease in Human Immunodeficiency Virus-Hepatitis C Coinfection: A Longitudinal Cohort Analysis
por: Costiniuk, Cecilia T., et al.
Publicado: (2016)

Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in Canada
por: Marathe, Gayatri, et al.
Publicado: (2022)

Frequent injection cocaine use increases the risk of renal impairment among hepatitis C and HIV coinfected patients
por: Rossi, Carmine, et al.
Publicado: (2016)

Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C–Coinfected Persons
por: Brunet, Laurence, et al.
Publicado: (2016)

How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?
por: Saeed, Sahar, et al.
Publicado: (2016)

Trends in cause-specific mortality in HIV–hepatitis C coinfection following hepatitis C treatment scale-up
por: Kronfli, Nadine, et al.
Publicado: (2019)

Estimating an individual-level deprivation index for HIV/HCV coinfected persons in Canada
por: Palayew, Adam, et al.
Publicado: (2021)

Disparities in direct acting antivirals uptake in HIV‐hepatitis C co‐infected populations in Canada
por: Saeed, Sahar, et al.
Publicado: (2017)

Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients
por: Rossi, Carmine, et al.
Publicado: (2018)

Responder Interferon λ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV–Hepatitis C Virus Coinfection
por: Moqueet, Nasheed, et al.
Publicado: (2016)

Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
por: Martinello, Marianne, et al.
Publicado: (2016)

Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV‐HCV co‐infected patients in Canada
por: Kronfli, Nadine, et al.
Publicado: (2018)

Effectiveness of Direct-Acting Antiviral Therapy in Patients With Human Immunodeficiency Virus–Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter Study
por: Kim, H Nina, et al.
Publicado: (2019)

Re-treatment of Hepatitis C Infection After Multiple Failures of Direct-Acting Antiviral Therapy
por: Fierer, Daniel S, et al.
Publicado: (2020)

Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy
por: Ghiglione, Yanina, et al.
Publicado: (2020)

T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy
por: Auma, Ann W N, et al.
Publicado: (2021)

Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study
por: Martel-Laferrière, Valérie, et al.
Publicado: (2017)

Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV–HCV Coinfection
por: Doyle, Mary-Anne, et al.
Publicado: (2019)

Predictors of Hepatitis C Treatment Failure After Using Direct-Acting Antivirals in People Living With Human Immunodeficiency Virus
por: Cachay, Edward R, et al.
Publicado: (2019)

Marijuana Smoking Does Not Accelerate Progression of Liver Disease in HIV–Hepatitis C Coinfection: A Longitudinal Cohort Analysis
por: Brunet, Laurence, et al.
Publicado: (2013)

Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus
por: Saeed, Sahar, et al.
Publicado: (2020)

Immunological Predictors of Nonresponse to Directly Acting Antiviral Therapy in Patients With Chronic Hepatitis C and Decompensated Cirrhosis
por: Childs, Kate, et al.
Publicado: (2017)

Microelimination of Chronic Hepatitis C by Universal Screening Plus Direct-Acting Antivirals for Incarcerated Persons in Taiwan
por: Yang, Tsung-Hua, et al.
Publicado: (2020)

Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection
por: Liu, Chen-Hua, et al.
Publicado: (2017)

Comparing direct acting antivirals for hepatitis C using observational data – Why and how?
por: Young, Jim, et al.
Publicado: (2020)

Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study
por: Gowda, Charitha, et al.
Publicado: (2018)

Development of Hepatocellular Carcinoma in Patients Aged 75–84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals
por: Ogawa, Eiichi, et al.
Publicado: (2020)

The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era in a United States Commercially Insured Population
por: Ferrante, Nicole D, et al.
Publicado: (2022)

Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients
por: Lo Re, Vincent, et al.
Publicado: (2015)

Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens
por: Akiyama, Matthew J, et al.
Publicado: (2021)

Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study
por: Isfordink, Cas J, et al.
Publicado: (2021)

Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics
por: Berenguer, Juan, et al.
Publicado: (2016)

Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons
por: Mocroft, Amanda, et al.
Publicado: (2020)

The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care
por: Cachay, Edward R., et al.
Publicado: (2015)

The Effect of Hepatitis C Virologic Clearance on Cardiovascular Disease Biomarkers in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
por: Chew, Kara W., et al.
Publicado: (2014)

Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment
por: Liu, Chun Jen, et al.
Publicado: (2021)

T-Cell Exhaustion in HIV-1/Hepatitis C Virus Coinfection Is Reduced After Successful Treatment of Chronic Hepatitis C
por: Caraballo Cortés, Kamila, et al.
Publicado: (2023)

HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1
por: Berenguer, Juan, et al.
Publicado: (2019)

Concomitant Treatment of Tuberculosis and Hepatitis C Virus in Coinfected Patients Using Serum Drug Concentration Monitoring
por: Ashkin, Alex, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_21e3b2the440qa55027borqfe7